Published on 20/11/2025

Common Pitfalls in Country & Site Feasibility Assessments—and How to Avoid Costly Delays

Understanding Country and Site Feasibility Assessments

Country and site feasibility assessments are critical steps in the clinical trial process, particularly when determining the most suitable locations for a specific study. The ultimate goal is to ensure a successful trial execution, adherence to timelines, and compliance with regulatory requirements. Country feasibility assessments evaluate a country’s regulations, healthcare infrastructure, and availability of patient populations, while site feasibility focuses on assessing individual sites within that country.

Given the growing complexity of clinical trials, especially in an environment governed by stringent regulations from bodies such as the FDA, EMA, and MHRA, this article aims to elucidate the common pitfalls encountered during these assessments and provide strategies for avoiding these costly mistakes.

Pitfall #1: Inadequate Regulatory Knowledge

One of the most common pitfalls in country and site feasibility assessments is inadequate knowledge of local regulatory requirements. Each country has unique regulations regarding ethical considerations, informed consent, and trial approvals.

Professionals conducting feasibility assessments must be well-versed in the specific regulations of the countries in which they are assessing sites. A failure to comply with local regulations can result in significant delays in getting the trial approved or even render the trial unfeasible altogether.

To avoid this pitfall:

• Conduct Comprehensive Research: Allocate sufficient resources to understand the regulatory environment in each potential country. This includes understanding clinical trial application processes, required documentation, and timelines.
• Engage Local Experts: Collaborate with local consultants or legal advisors who have a deep understanding of the regulatory landscape. This partnership can lend valuable insights and facilitate smoother navigation through local processes.
• Utilize Existing Resources: Leverage resources and databases that provide updated information on regulatory guidelines, such as the ClinicalTrials.gov.

Pitfall #2: Underestimating Site Capability and Capacity

Another critical misstep is underestimating the site’s capability and capacity to conduct the clinical trial. Not all clinical sites are created equal, and previous experience with similar trials, patient recruitment capabilities, and availability of necessary infrastructure can greatly influence trial success.

To avoid issues related to site selection:

• Assess Past Performance: Review the performance history of sites in question, focusing on metrics such as recruitment timelines and data quality in previous sdr clinical trials.
• Evaluate Local Patient Populations: Research the demographics of the area surrounding the proposed sites to ensure adequate patient availability for the trial criteria.
• Conduct Site Visits: Insist on performing site visits to evaluate the physical site capabilities, including staff expertise and available technology. This hands-on approach often reveals insights that desk research cannot.

Pitfall #3: Inadequate Feasibility Questionnaires

The feasibility questionnaire is a vital tool designed to provide insights into site readiness and capability. However, inadequately designed questionnaires can lead to misleading results.

To mitigate this risk, follow these best practices:

• Involve Cross-Functional Teams: Include input from clinical operations, regulatory affairs, and data management teams to ensure that the questionnaire covers all relevant aspects.
• Tailor Questions to Specific Trials: Customize the questionnaire to align with the specific requirements of the clinical trial, including therapy type and target population.
• Define Clear Metrics of Success: Establish benchmarks for what constitutes a positive response, enabling better assessment and comparison across sites.

Pitfall #4: Failure to Account for Local Healthcare Infrastructure

Ignoring the capabilities of local healthcare infrastructure can lead to unfavorable outcomes. Understanding the healthcare delivery model in each country or region can help set realistic study timelines and expectations.

Strategies to factor in local infrastructure include:

• Analyze Healthcare Systems: Assess the structure of the healthcare system in each country, noting the variation in public and private sector roles.
• Evaluate Emergency Protocols: Ensure that sites have necessary emergency procedures and are compliant with relevant local laws.
• Understand Patient Access: Recognize the potential barriers patients can face when accessing clinical trials, such as transportation or financial concerns.

Pitfall #5: Not Engaging Investigators Early

The significance of early engagement with principal investigators cannot be overstated. It is vital to ascertain their availability, willingness to participate, and insight into potential challenges before formally committing to a site.

Combat this pitfall by:

• Scheduling Early Discussions: Arrange initial meetings with potential investigators to understand their level of interest and concerns ahead of time.
• Involving Investigators in Planning: Encourage them to share their insights regarding local patient recruitment and patient retention strategies based on their experience.
• Review Their Previous Work: Study past involvement in clinical trials, including any publications or studies that highlight their capabilities.

Pitfall #6: Inadequate Risk Assessment

A comprehensive risk assessment should precede final feasibility decisions. Failing to identify potential risks can have serious repercussions, including delays, increased costs, and potential non-compliance.

To effectively assess risks, consider the following:

• Utilize Risk Management Tools: Implement risk management frameworks and tools specifically tailored for clinical trials to ensure comprehensive coverage of potential risks.
• Identify Key Risk Indicators: Establish metrics that signify warning signs that could jeopardize feasibility or overall trial success.
• Regular Updates: Given the dynamic nature of clinical trials, regularly update assessments to reflect changes in site readiness or regulatory landscapes.

Pitfall #7: Ignoring Site Budget and Financial Viability

A cornerstone of feasibility assessments lies in understanding the financial viability of selected sites. Failure to engage with sites on financial matters early can lead to misunderstandings and ultimately, site dropout.

To address budgeting concerns:

• Transparent Financial Discussions: Initiate clear discussions regarding site budgets, sponsorship, and the allocation of resources right at the start.
• Review Local Costs: Ensure comprehensive financial assessments of the local costs associated with clinical trial execution, including staff salaries, site overhead, and patient compensation.
• Plan for Unforeseen Costs: Anticipate hidden expenses by allowing a buffer in the budget to accommodate potential increases in operational costs.

Conclusion

Country and site feasibility assessments are complex yet indispensable components of the clinical trial process. By being aware of the common pitfalls and taking the necessary steps to address them, clinical operations, regulatory affairs, and medical affairs professionals can enhance the chances of successful trial execution. Proactive engagement and thorough assessment practices will mitigate delays and ensure compliance with international regulations, ultimately contributing to the projected timelines for bringing innovative treatments to market.

Effective trial search clinical trials should encapsulate comprehensive planning, stakeholder involvement, and a robust understanding of local conditions. Incorporating these best practices will not only streamline your feasibility assessments but will also promote sustainable and successful clinical development initiatives.